Limits...
Gastroprotective Activities of Sennoside A and Sennoside B via the Up-Regulation of Prostaglandin E2 and the Inhibition of H(+)/K(+)-ATPase.

Hwang IY, Jeong CS - Biomol Ther (Seoul) (2015)

Bottom Line: It was observed that both sennoside A and sennoside B increased prostaglandin E2 (PGE2) levels and inhibited H(+)/K(+)-ATPase (proton pump).Furthermore, sennoside A and B increased PGE2 in a concentration-dependent manner.Our results thus suggest that sennoside A and sennoside B possess significant gastroprotective activities and they might be useful for the treatment of gastric disease.

View Article: PubMed Central - PubMed

Affiliation: College of Pharmacy, Duksung Women's University, Seoul 132-714, Republic of Korea.

ABSTRACT
Sennoside A (erythro) and sennoside B (threo) are dianthrone glycosides and diastereomers. We investigated their abilities to prevent the gastric lesions associated with diseases, such as, gastritis and gastric ulcer. To elucidate their gastroprotective effects, the inhibitions of HCl•EtOH-induced gastritis and indomethacin-induced gastric ulcers were assessed in rats. It was observed that both sennoside A and sennoside B increased prostaglandin E2 (PGE2) levels and inhibited H(+)/K(+)-ATPase (proton pump). In a rat model, both compounds reduced gastric juice, total acidity and increased pH, indicating that proton pump inhibition reduces gastric acid secretion. Furthermore, sennoside A and B increased PGE2 in a concentration-dependent manner. In a gastric emptying and intestinal transporting rate experiment, both sennoside A and sennoside B accelerated motility. Our results thus suggest that sennoside A and sennoside B possess significant gastroprotective activities and they might be useful for the treatment of gastric disease.

No MeSH data available.


Related in: MedlinePlus

H+/K+-ATPase inhibitory activities of sennoside A and sennoside B. The values are mean ± S.E.M. of 3 experiments. Significant difference *p<0.05; **p<0.01 compared to the control group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4556206&req=5

f5-bt-23-458: H+/K+-ATPase inhibitory activities of sennoside A and sennoside B. The values are mean ± S.E.M. of 3 experiments. Significant difference *p<0.05; **p<0.01 compared to the control group.

Mentions: When we measured the H+/K+-ATPase activities of sennoside A and B, pantoprazole (the positive control) exhibited inhibitions of 41.1% and 42.4% at 50 μM and 100 μM, whereas sennoside A showed dose-dependent inhibitions of 17.3% and 27.1% at 50 μM and 100 μM. Similarly, sennoside B showed significant inhibition at 38.8% and 40.2% at 50 μM and 100 μM, respectively (Fig. 5).


Gastroprotective Activities of Sennoside A and Sennoside B via the Up-Regulation of Prostaglandin E2 and the Inhibition of H(+)/K(+)-ATPase.

Hwang IY, Jeong CS - Biomol Ther (Seoul) (2015)

H+/K+-ATPase inhibitory activities of sennoside A and sennoside B. The values are mean ± S.E.M. of 3 experiments. Significant difference *p<0.05; **p<0.01 compared to the control group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4556206&req=5

f5-bt-23-458: H+/K+-ATPase inhibitory activities of sennoside A and sennoside B. The values are mean ± S.E.M. of 3 experiments. Significant difference *p<0.05; **p<0.01 compared to the control group.
Mentions: When we measured the H+/K+-ATPase activities of sennoside A and B, pantoprazole (the positive control) exhibited inhibitions of 41.1% and 42.4% at 50 μM and 100 μM, whereas sennoside A showed dose-dependent inhibitions of 17.3% and 27.1% at 50 μM and 100 μM. Similarly, sennoside B showed significant inhibition at 38.8% and 40.2% at 50 μM and 100 μM, respectively (Fig. 5).

Bottom Line: It was observed that both sennoside A and sennoside B increased prostaglandin E2 (PGE2) levels and inhibited H(+)/K(+)-ATPase (proton pump).Furthermore, sennoside A and B increased PGE2 in a concentration-dependent manner.Our results thus suggest that sennoside A and sennoside B possess significant gastroprotective activities and they might be useful for the treatment of gastric disease.

View Article: PubMed Central - PubMed

Affiliation: College of Pharmacy, Duksung Women's University, Seoul 132-714, Republic of Korea.

ABSTRACT
Sennoside A (erythro) and sennoside B (threo) are dianthrone glycosides and diastereomers. We investigated their abilities to prevent the gastric lesions associated with diseases, such as, gastritis and gastric ulcer. To elucidate their gastroprotective effects, the inhibitions of HCl•EtOH-induced gastritis and indomethacin-induced gastric ulcers were assessed in rats. It was observed that both sennoside A and sennoside B increased prostaglandin E2 (PGE2) levels and inhibited H(+)/K(+)-ATPase (proton pump). In a rat model, both compounds reduced gastric juice, total acidity and increased pH, indicating that proton pump inhibition reduces gastric acid secretion. Furthermore, sennoside A and B increased PGE2 in a concentration-dependent manner. In a gastric emptying and intestinal transporting rate experiment, both sennoside A and sennoside B accelerated motility. Our results thus suggest that sennoside A and sennoside B possess significant gastroprotective activities and they might be useful for the treatment of gastric disease.

No MeSH data available.


Related in: MedlinePlus